Peripheral Arterial Disease (PAD) Therapeutics Market 2015-2022: Global Strategic Business Report 2017 - Anti-Platelet Drugs Spearheading the Battle Against PAD - Research and Markets

News provided by

Mar 06, 2017, 11:15 ET

DUBLIN, Mar. 6, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Peripheral Arterial Disease (PAD) Therapeutics - Global Strategic Business Report" report to their offering.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.

This report analyzes the worldwide markets for Peripheral Arterial Disease (PAD) Therapeutics in US$ Million.

The report profiles 23 companies including many key and niche players such as

AstraZeneca Plc. (UK)
Bayer HealthCare Pharmaceuticals (Germany)
Bristol-Myers Squibb Company (US)
Merck & Co., Inc. (US)
Proteon Therapeutics, Inc. (US)
Sanofi S.A. (France)
Symic Bio, Inc. (US)
TheraVasc Inc. (US)

Key Topics Covered:

1. INDUSTRY OVERVIEW

A Prelude
PAD Statistics
Critical Limb Ischemia
An Insight
High Costs
A Cause of Concern

2. PAD THERAPEUTICS

Anti-Platelet Drugs: Spearheading the Battle against PAD
Key Drugs for Arterial Disease
Clopidogrel (Plavix)
Prasugrel (Effient)
Ticagrelor (Brilinta)
Vorapaxar (Zontivity)
Dual Antiplatelet Therapy (DAPT) for PAD
Entry of Generics Tones Down Growth in Major Markets
Brilinta Fails to Meet Expectations in EUCLID Trial
Xarelto Pins Hope on COMPASS and VOYAGER trials
Other Pipeline Drugs for Peripheral Arterial Disease (PAD)
Cholesterol-Lowering Drugs: A Key Weapon in the Anti-PAD Arsenal

3. MACRO GROWTH DRIVERS

Aging
A Key Driver
High Diabetes Incidence Worldwide: Key Market Opportunity for PAD Therapeutics

4. PERIPHERAL ARTERIAL DISEASE (PAD) - AN OVERVIEW

Peripheral Arterial Disease: Understanding the Stealthy Peril
Causes of PAD
Tobacco Use
Diabetes
Dyslipidemia
Hypertension
Causes of PAD in Lower Extremities
Atherosclerosis
Blood Clotting
Link Established between Depression and PAD
Ethyl-EPA Intake Proves Favorable for PAD Sufferers
PAD Risk Factors
Symptoms of PAD
Claudication
Rest Pain
Other Symptoms
Prognosis of PAD
Diagnosis of PAD
Ankle Brachial Index (ABI)
Ankle-Brachial Index and Associated Severity of Peripheral Arterial Disease
Magnetic Resonance Angiography (MRA) and CT Scan
Control of PAD
Classification of PAD Severity
Methods for Avoiding PAD Complications
Treatment Options for Peripheral Arterial Disease
A General Perspective
Lifestyle Changes

5. COMPANIES INTO GENE THERAPY FOR PAD

AnGes MG, Inc. (Japan)
Athersys, Inc. (US)
Betagenon AB (Sweden)
CardioVascular BioTherapeutics, Inc. (US)
Celgene Corporation (US)
ID Pharma Co., Ltd. (Japan)
miRagen Therapeutics, Inc. (US)
Multi Gene Vascular Systems Ltd (Israel)
ViroMed Co. Ltd. (Korea)

6. CLINICAL STUDIES/CORPORATE INITIATIVES

AstraZeneca Announces Results of EUCLID Trial
USPTO Extends Patent Term for Bayer's Rivaroxaban
Bayer and Janssen Expand Clinical Development Programme for Rivaroxaban
FDA Approves Merck's Zontivity

7. FOCUS ON SELECT GLOBAL PLAYERS

8. GLOBAL MARKET PERSPECTIVE

Total Companies Profiled: 23 (including Divisions/Subsidiaries 25)

The United States (9)
Canada (1)
Japan (2)
Europe (7)
- France (1)
- Germany (2)
- The United Kingdom (1)
- Rest of Europe (3)
Asia-Pacific (Excluding Japan) (6)

For more information about this report visit http://www.researchandmarkets.com/research/jxndrb/peripheral

Media Contact:

Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets